 Home > Active Ingredient News > Antitumor Therapy > Front Oncol: The effect of TMB status on the efficacy of anti-HER2 therapy in HER2-positive advanced gastric cancer (AGC)

Front Oncol: The effect of TMB status on the efficacy of anti-HER2 therapy in HER2-positive advanced gastric cancer (AGC)

 Last Update: 2021-12-24
 Source: Internet
 Author: User

Tags

ebna positive

adenocarcinoma prostate cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Trastuzumab ( Trastuzumab ) is a humanized monoclonal antibody targeting her2 and has been recommended as a HER2- positive late stageThe first-line treatment for patients with gastric cancer (AGC) .
However, the effect of anti- HER2 therapy on HER2- positive AGC based on tumor mutant burden (TMB) status is still unclear .
Recently, South Korean scholars to carry out research, according to TMB assess the state of the anti- HER2 therapy in HER2 -positive AGC efficacy .
Related results were published in Frontiers in Oncology journal .

Trastuzumab ( Trastuzumab ) is a humanized monoclonal antibody targeting her2 and has been recommended as a HER2- positive late stageThe first-line treatment for patients with gastric cancer (AGC) .

However, the effect of anti- HER2 therapy on HER2- positive AGC based on tumor mutant burden (TMB) status is still unclear .
Recently, South Korean scholars to carry out research, according to TMB assess the state of the anti- HER2 therapy in HER2 -positive AGC efficacy .
Related results were published in Frontiers in Oncology journal .
Trastuzumab (Trastuzumab) is ahumanized monoclonal antibodytargetingher2and has been recommended as aHER2-positive late stageStomach cancerThe first-line treatment for patients with gastric cancer (AGC) .
(tumor mutant burden, TMB) status HER2- positive AGC for anti- HER2 therapy is still unclear .
TMB state evaluation of the anti HER2 in the treatment of HER2 -positive AGC efficacy .
Related results were published in Frontiers in Oncology journal .

Study of 31 is embodiment HER2 positive AGC patients next generation sequencing (NGS) , comprising TMB analyzed, these patients received trastuzumab plus chemotherapy as first-line therapy, including recurrence (n = 8) or metastasis (n = 23) Tumor patients
.

The 31 patients included had a median age of 57.

Clinical features

Clinical features Clinical features

The median follow-up time was 10.
8 months (range 1.
7-20.
9)
.

The median treatment period was 7.

The median follow-up time was 10.

Efficacy evaluation

The median DOR of CR or PR patients was 6.
1 months (IQR, 3.
4-9.
6)
.

The median PFS of all patients was 9.

The median DOR of CR or PR patients was 6.

PFS and OS in all patients

According to TMB status, the median PFS of patients with high TMB has not been reached, and the median PFS of patients with low TMB is 8.
0 months (95% CI, 7.
6-8.
5) (HR = 0.
122; 95% CI, 0.
016-0.
954, P = 0.
019 )
.

The median OS of patients with high TMB has not yet been reached, and the median OS of patients with low TMB is 14.

According to TMB status, the median PFS of patients with high TMB has not been reached, and the median PFS of patients with low TMB is 8.

PFS and OS in patients with high and low TMB

PFS and OS of high and low TMB patients PFS and OS of high and low TMB patients

In summary, studies have shown that the status of TMB may be a new biomarker predicting the efficacy of trastuzumab combined with chemotherapy in the treatment of HER2-positive AGC patients
.

In summary, the research shows that the research shows that the status of TMB may be a new biomarker predicting the efficacy of trastuzumab combined with chemotherapy in the treatment of HER2-positive AGC patients

Original source:

Kim HR, Ahn S, Jo H, Kim H, Hong J, Lee J, Lim HY, Kang WK and Kim ST (2021) The Impact of Tumor Mutation Burden on the Effect of Frontline Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 -Positive Advanced Gastric Cancers.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.